Open AccessSelection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission
Author(s) -
Marina Giuliano,
Lucia Palmisano,
Clementina Maria Galluzzo,
Roberta Amici,
Elena Germinario,
Pius Okong,
Praxedes Kituuka,
Francis Mmirro,
Michele Magoni,
Stefano Vella
Publication year - 2003
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200307040-00022
Subject(s) - zidovudine , lamivudine , resistance mutation , medicine , reverse transcriptase inhibitor , regimen , virology , transmission (telecommunications) , pregnancy , obstetrics , reverse transcriptase , sida , human immunodeficiency virus (hiv) , viral disease , virus , biology , genetics , polymerase chain reaction , hepatitis b virus , electrical engineering , gene , engineering
Two zidovudine/lamivudine regimens for the prevention of HIV perinatal transmission were studied for the selection of resistance mutations. The M184V mutation was detected one week after delivery in six out of fifty women (12%) who received the regimen prepartum, intrapartum and postpartum, and was no longer present 3 months later. No nucleoside reverse transcriptase inhibitor resistance-associated mutations were detected in 50 women who received zidovudine/lamivudine intrapartum and postpartum only. No association with the risk of perinatal transmission was found.